Chimeric Therapeutics Ltd

CHM

Company Profile

  • Business description

    Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

  • Contact

    62 Lygon Street
    Level 3, Carlton South
    MelbourneVIC3053
    AUS

    T: +61 398245254

    https://www.chimerictherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,833.604.900.06%
CAC 407,753.2414.820.19%
DAX 4023,881.9391.820.39%
Dow JONES (US)44,484.4210.52-0.02%
FTSE 1008,824.3149.620.57%
HKSE24,069.94151.47-0.63%
NASDAQ20,393.13190.240.94%
Nikkei 22539,785.9023.420.06%
NZX 50 Index12,704.4879.81-0.62%
S&P 5006,227.420.000.00%
S&P/ASX 2008,595.801.90-0.02%
SSE Composite Index3,461.156.360.18%

Market Movers